The emerging therapy of tirzepatide peptide represents a significant advance in the management of the condition. Distinct from existing drugs, tirzepatide affects multiple pathways – glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) – resulting in improved glucose management and potential reduction in weight